for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AmerisourceBergen Corp.

ABC.N

Latest Trade

103.08USD

Change

2.60(+2.59%)

Volume

87,606

Today's Range

100.54

 - 

103.79

52 Week Range

72.20

 - 

110.96

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Lilly's Neutralizing Antibody Receives FDA Emergency Use Nod For Treatment Of Recently Diagnosed COVID-19

Nov 9 (Reuters) - Eli Lilly and Co <LLY.N>::LILLY'S NEUTRALIZING ANTIBODY BAMLANIVIMAB (LY-COV555) RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR THE TREATMENT OF RECENTLY DIAGNOSED COVID-19.ELI LILLY AND CO - U.S. GOVERNMENT WILL ALLOCATE 300,000 DOSES OF BAMLANIVIMAB TO HIGH-RISK PATIENTS, WITH NO OUT-OF-POCKET COSTS FOR MEDICATION.ELI LILLY AND CO - FDA GRANTED EUA FOR CO'S INVESTIGATIONAL NEUTRALIZING ANTIBODY BAMLANIVIMAB (LY-COV555) 700 MG.ELI LILLY AND CO - EUA INCLUDES A WARNING FOR HYPERSENSITIVITY INCLUDING ANAPHYLAXIS AND INFUSION-RELATED REACTIONS.ELI LILLY - WILL BEGIN SHIPPING BAMLANIVIMAB IMMEDIATELY TO AMERISOURCEBERGEN, WHICH WILL DISTRIBUTE IT AS DIRECTED BY U.S. GOVERNMENT'S ALLOCATION PROGRAM.

Amerisourcebergen Reports Q4 Adjusted Earnings Per Share $1.89

Nov 5 (Reuters) - Amerisourcebergen Corp <ABC.N>::AMERISOURCEBERGEN REPORTS FISCAL 2020 FOURTH QUARTER AND YEAR END RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $1.89.Q4 GAAP LOSS PER SHARE $23.74.Q4 EARNINGS PER SHARE ESTIMATE $1.85 -- REFINITIV IBES DATA.REVENUE OF $49.2 BILLION FOR Q4, A 7.9 PERCENT INCREASE YEAR-OVER-YEAR.RECORDED A $6.6 BILLION ($5.5 BILLION AFTER TAX) CHARGE, WHICH IS EXCLUDED FROM ITS ADJUSTED (NON-GAAP) QTRLY RESULTS.AMERISOURCEBERGEN - IS IN ADVANCED DISCUSSIONS, WHICH ARE ONGOING, TO REACH A GLOBAL SETTLEMENT TO BE PAID OVER AN 18-YEAR PERIOD TO RESOLVE CASES.EXPECTS 2021 REVENUE GROWTH IN MID-SINGLE DIGIT PERCENT RANGE, ON AN ADJUSTED BASIS.SEES 2021 ADJUSTED DILUTED EARNINGS PER SHARE TO BE IN RANGE OF $8.20 TO $8.45..SEES 2021 ADJUSTED FREE CASH FLOW TO BE ABOUT $1.5 BILLION.

Amerisourcebergen Units Entered Amended & Restated Receivables Sale Agreement

Oct 19 (Reuters) - Amerisourcebergen Corp <ABC.N>::AMERISOURCEBERGEN - ON OCT 16 UNITS ENTERED AMENDED & RESTATED RECEIVABLES SALE AGREEMENT, AMONG AMERISOURCEBERGEN DRUG CORPORATION & ASD SPECIALTY.AMERISOURCEBERGEN - AMENDMENTS ADDED ASD AS A NEW ORIGINATOR UNDER SECURITIZATION FACILITY.AMERISOURCEBERGEN CORP - SECURITIZATION FACILITY HAS A BASE LIMIT OF US$1,450 MILLION.AMERISOURCEBERGEN - SECURITIZATION FACILITY HAS OPTION TO INCREASE COMMITMENTS OF PARTICIPATING BANKS, BY ADDITIONAL US$250 MILLION.

HHS Says Gilead Anticipates Producing Sufficient Quantities Of Veklury To Meet Current Needs

Oct 1 (Reuters) - HHS::HHS SAYS GILEAD ANTICIPATES PRODUCING SUFFICIENT QUANTITIES OF VEKLURY TO MEET CURRENT NEEDS, FUTURE DEMANDS FROM ANY WAVES OF SARS-COV-2 INFECTIONS.HHS SAYS COST OF VEKLURY WILL NOT CHANGE IN TRANSITION FROM U.S. GOVERNMENT OVERSIGHT OF ALLOCATION TO DIRECT COMMERCIAL SALES.HHS SAYS HOSPITALS WILL CONTINUE TO PAY NO MORE THAN GILEAD’S WHOLESALE ACQUISITION PRICE OF VEKLURY, ABOUT $3,200 PER TREATMENT COURSE.HHS SAYS AMERISOURCEBERGEN WILL REMAIN SOLE DISTRIBUTOR OF VEKLURY THROUGH END OF YEAR TO ENSURE CONSISTENCY & CONTINUITY OF DISTRIBUTION PROCESS.HHS SAYS FEDERAL GOVERNMENT OVERSIGHT OF THE ALLOCATION OF VEKLURY IS NOT REQUIRED BECAUSE THE DRUG IS NO LONGER A SCARCE RESOURCE.HHS SAYS BEGINNING OCT 1, 2020, AMERICAN HOSPITALS CAN PURCHASE VEKLURY (REMDESIVIR) DIRECTLY FROM DRUG’S DISTRIBUTOR.HHS SAYS CURRENT SUPPLY OF VEKLURY EXCEEDS MARKET DEMAND AS EVIDENCED BY RECENT ALLOCATION NUMBERS FROM HHS’ OFFICE OF THE ASPR.

U.S. States Seek $26.4 Bln From Drug Companies In Opioid Litigation - WSJ

Aug 18 (Reuters) - :U.S. STATES SEEK $26.4 BILLION FROM DRUG COMPANIES IN OPIOID LITIGATION- WSJ.TALKS WITH U.S. STATES INVOLVE MCKESSON, AMERISOURCEBERGEN, CARDINAL HEALTH, JOHNSON & JOHNSON - WSJ.

AmerisourceBergen Q3 GAAP Earnings Per Share $1.41

Aug 5 (Reuters) - Amerisourcebergen Corp <ABC.N>::AMERISOURCEBERGEN REPORTS FISCAL 2020 THIRD QUARTER RESULTS.SEES FY 2020 ADJUSTED EARNINGS PER SHARE $7.80 TO $7.95.Q3 ADJUSTED EARNINGS PER SHARE $1.85.Q3 GAAP EARNINGS PER SHARE $1.41.Q3 EARNINGS PER SHARE ESTIMATE $1.57 -- REFINITIV IBES DATA.REVENUES OF $45.4 BILLION FOR Q3, A 0.3 PERCENT INCREASE YEAR-OVER-YEAR.Q3 REVENUE VIEW $44.66 BILLION -- REFINITIV IBES DATA.

AmerisourceBergen Corp Prices $500 Mln 2.800% Senior Notes Due 2030

May 12 (Reuters) - AmerisourceBergen Corp <ABC.N>::AMERISOURCEBERGEN PRICES $500 MILLION 2.800% SENIOR NOTES DUE 2030.

Amerisourcebergen Sees 2020 Rev Growth In Low- To Mid-Single Digit Percent Range

May 7 (Reuters) - AmerisourceBergen Corp <ABC.N>::AMERISOURCEBERGEN REPORTS FISCAL 2020 SECOND QUARTER RESULTS.SEES FY 2020 ADJUSTED EARNINGS PER SHARE $7.35 TO $7.65.Q2 ADJUSTED EARNINGS PER SHARE $2.40.Q2 GAAP EARNINGS PER SHARE $4.64.Q2 EARNINGS PER SHARE ESTIMATE $2.27 -- REFINITIV IBES DATA.ADJUSTED DILUTED EPS GUIDANCE RANGE REVISED TO $7.35 TO $7.65 FOR FISCAL 2020.REVENUES OF $47.4 BILLION FOR Q2, A 9.5% PERCENT INCREASE YEAR-OVER-YEAR.REVISED ITS ADJUSTED DILUTED EPS GUIDANCE FOR FISCAL 2020 TO A RANGE OF $7.35 TO $7.65, FROM $7.55 TO $7.80 PREVIOUSLY.SEES 2020 REVENUE GROWTH IN THE LOW- TO MID-SINGLE DIGIT PERCENT RANGE.SEES 2020 REVENUE GROWTH IN LOW- TO MID-SINGLE DIGIT PERCENT RANGE.

PIRC Recommends Amerisourcebergen Shareholders To Vote Against Election Of Steven H Collis As Director

Feb 26 (Reuters) - PIRC::PROXY ADVISORY FIRM PIRC RECOMMENDS AMERISOURCEBERGEN CORP SHAREHOLDERS TO VOTE AGAINST RESOLUTION TO ELECT CEO STEVEN H COLLIS AS DIRECTOR.PROXY ADVISORY FIRM PIRC RECOMMENDS AMERISOURCEBERGEN CORP SHAREHOLDERS TO VOTE AGAINST RESOLUTION TO RATIFY ERNST & YOUNG LLP AS AUDITORS.

Calif. AG's Office: opioid settlement talks with distributors ongoing

Feb 14 (Reuters) - :California AG's office says "far along in the process of talks" and still negotiating with distributors on opioid settlement.California AG's office says to suggest settlement talks with distributors regarding opioids are off would be inaccurate.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up